Beam Therapeutics
BEAM
NASDAQ
IPO2020
about BEAM
Beam Therapeutics specializes in developing precise gene-editing treatments using CRISPR technology, targeting diseases at their genetic source to address unmet patient needs.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $29.50 | $36.44 | $29.16 | $2.8B | 7.04M |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| -$1.10 | n/a | 356.96 | -1307.60% | -1162.38% | 2.67% |